Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

200P - Lipid changes during endocrine therapy in breast cancer patients: The results of a 5-year real-world retrospective analysis

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Breast Cancer

Presenters

Tao He

Citation

Annals of Oncology (2020) 31 (suppl_4): S303-S339. 10.1016/annonc/annonc267

Authors

T. He1, Y. Wu1, Y. Fei2, Q. Lv3, J. Chen3

Author affiliations

  • 1 Department Of Breast Surgery, West China Hospital/West China School of Medicine, Sichuan University, 610041 - Chengdu/CN
  • 2 Prophylactic Medicine, West China School of Public Health/West China fourth Hospital, Sichuan University, 610041 - Chengdu/CN
  • 3 Department Of Breast Surgery,, West China Hospital, Sichuan University,, 610041 - Chengdu/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 200P

Background

Adjuvant endocrine therapy may cause alterations in serum lipids in postoperative breast cancer (BC) patients, but the specific alterations caused by different endocrine agents remain unclear. The aim of this study was to investigate the status of serum lipids during the 5-year endocrine therapy and to compare the effects of different endocrine drugs on lipid profiles.

Methods

We retrospectively analysed the lipid profiles during the 5-yera treatment of 1487 consecutive postoperative BC patients from February 2009 to December 2016. Lipid parameters include triglycerides (TG), total cholesterols (TC), low-density lipoprotein (LDL-C) and high-density lipoprotein (HDL-C). The levels of TG, TC, HDL and LDL were measured at baseline and 1, 2, 3, 4 and 5 years following the initiation of endocrine therapy, respectively.

Results

For premenopausal BC patients, LDL levels rapidly decreased at 1 year in the tamoxifene (TAM) group compared with baseline (p<0.05), and the decline remained for the following 4 years. Also, compared with the control group, LDL was significantly lower in TAM group at all the assessment time points (p<0.05). Similarly, TC also decreased in the TAM group compared with baseline (p<0.05) and compared with the control group, TC was also lower for the first 4 years. For postmenopausal BC patients, there was no statistical difference in the lipid profiles (TG, TC, LDL and HDL) in letrozole (LET), anastrozole (ANA) and exemestane (EXE) group compared with the control group, respectively. As for patients received TAM, compared with the control group, TC decreased at 1 year; and LDL decreased at 1 and 2 year.

Conclusions

TAM may improve serum lipids mainly on LDL and TC levels in premenopausal BC patients. While for those postmenopausal, aromatase inhibitors (AI) may have no adverse effects on lipid profiles; and TAM may have little beneficial effects on serum lipid.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

West China School of Medicine/West China Hospital, Sichuan University.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.